Nuvectis Pharma, Inc. - Common Stock (NVCT)
Nuvectis Pharma, Inc. - Common Stock (NVCT) last closed at $18.95 (as of 2026-08-07). On Shishin's four-engine momentum model it scored 57/100, flagged by the Suzaku engine (Extended) on its most recent scan appearance (2026-07-01). It has surfaced in 2 daily scans since 2026-06-25. The figures below are research data, the Shishin Score and the momentum, trend, and volatility indicators the engines observe, not investment advice.
Price updates daily; the engine read reflects NVCT's most recent scan appearance. Shishin's live daily signals are published each morning on the rankings board.
NVCT did not make Shishin's board on 2026-08-07: below the liquidity floor (under about $20M traded/day). This is a mechanical screen result, not a view on the company.
NVCT's Shishin Score has faded 12 points (from 69 to 57/100) across its recent scans, momentum-of-score is cooling.
What is NVCT's Shishin momentum score?
As of 2026-07-01, NVCT scores 57/100 on Shishin's four-engine composite, flagged by the Suzaku engine. The score blends momentum, trend, and volatility indicators on a 0 to 100 scale.
Is NVCT showing a momentum setup?
NVCT's current setup state is "Extended." This describes what the engines observe in the chart structure, it is a data classification, not a recommendation to buy or sell.
Which Shishin engine flags NVCT?
Most recently the Suzaku engine. Each of the four guardians is tuned for a different market regime.
How often has NVCT appeared in Shishin scans?
NVCT has appeared in 2 daily scans since 2026-06-25. Recurring appearances indicate a persistent setup; one-off appearances are more transient.
How is the Shishin Score calculated?
The Shishin Score (0 to 100) is a weighted blend of momentum (multi-horizon returns), trend (moving-average stack, distance from MAs), and volatility/liquidity (ADR, ATR, dollar volume) indicators, scored per the engine active for the current market regime.
Research data, not investment advice. Shishin publishes what its systematic engines observe; it does not recommend buying or selling any security, and is not a registered investment adviser or broker-dealer. See our risk disclosure.